Phd Candidate - SOM: The Role of Interferon Lambdas in Liver Inflammation and Fibrosis

at Western Sydney University - Graduate Research School

What does the scholarship provide?

Domestic candidates will receive a tax-free stipend of $30,000 per annum for up to 3 years to support living costs, supported by the Research Training Program (RTP) Fee Offset. International candidates will receive a tax-free stipend of $30,000 per annum for up to 3 years to support living costs. Those with a strong track record will be eligible for a tuition fee waiver. Support for conference attendance, fieldwork and additional costs as approved by the School.

International candidates are required to hold an Overseas Student Health Care (OSHC) insurance policy for the duration their study in Australia. This cost is not covered by the scholarship.

Eligibility criteria

We welcome applicants from a range of backgrounds, that possess laboratory experience and a background in medical/health science and/or molecular biology. In particular, the project is suitable for candidates with strong interests in the immunology of chronic hepatic and gastrointestinal disease.

The successful applicant should: hold qualifications and experience equal to one of the following (i) an Australian First Class Bachelor (Honours) degree, (ii) coursework Masters with at least 25% research component, (iii) Research Masters degree, or (iv) equivalent overseas qualifications. demonstrate strong academic performance in subjects relevant to immunology and disease. understand the importance of identifying the mechanisms of disease in order to generate novel treatments and interventions. be willing to learn novel lab based and analytical techniques using a variety of advanced instrumentation. be enthusiastic and highly motivated to undertake further study at an advanced level.

International applicants must demonstrate English language proficiency.

Penrith New South Wales Australia
OTHER
2019-05-09
2019-06-08

If you apply for this position please say you saw it on The Conversation.